Dec 31, 2020
0 0

Sinopharm vaccine approved for market entry in China

The State Food and Drug Administration has approved the entry into the market of Sinopharm’s inactivated COVID-19 vaccine, RIA Novosti reported, citing China Central Television.

It is noted that the China National Biotech Group’s vaccine has been approved for market entry with additional conditions.

Clinical trial data indicate that the vaccine is 79.34% effective. However, monitoring of the duration and effectiveness of the vaccine is still required.

Earlier it was reported that China intends to vaccinate 50 million people against COVID-19 by mid-February, vaccination is scheduled to be completed by February 15.

It also became known that Kiev is negotiating with China on the supply of vaccines against COVID-19. Prior to that, Ukrainian President Volodymyr Zelensky complained that it was impossible to explain to the country’s residents why they should not receive Russian vaccines against coronavirus.

Article Categories:

Leave a Reply